Persistent immune abnormalities discriminate post-COVID syndrome from convalescence

Julia Sbierski-Kind\textsuperscript{1,2}, Stephan Schlickeiser\textsuperscript{3,4}, Svenja Feldmann\textsuperscript{5}, Veronica Ober\textsuperscript{6}, Eva Grüner\textsuperscript{5}, Claire Pleimeding\textsuperscript{5}, Leonard Gilberg\textsuperscript{5}, Isabel Brand\textsuperscript{6}, Nikolas Weigl\textsuperscript{7}, Mohamed I. M. Ahmed\textsuperscript{6,8}, Gerardo Ibarra\textsuperscript{2,9}, Michael Ruzicka\textsuperscript{9,10}, Christopher Benesch\textsuperscript{9,11}, Anna Pernpruner\textsuperscript{6,11}, Elisabeth Valdinoci\textsuperscript{9,11}, Michael Hoelscher\textsuperscript{6,8}, Kristina Adorjan\textsuperscript{9,12}, Hans Christian Stubbe\textsuperscript{6,9,11}, Michael Pritsch\textsuperscript{6,8}, Ulrich Seybold\textsuperscript{5}, Johannes Bogner\textsuperscript{5,6}, Julia Roider\textsuperscript{5,6} on behalf of the Post Covid Care and KoCo19 study groups

Affiliations:

1. Department of Medicine IV, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.
2. Department of Internal Medicine IV, Division of Diabetology, Endocrinology and Nephrology, University Hospital, Eberhard-Karls-Universität Tübingen, Tübingen, Germany.
3. Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Medical Immunology, Augustenburger Platz 1, 13353 Berlin, Germany.
4. Berlin Institute of Health (BIH) at Charité - Universitätsmedizin Berlin, BIH Center for Regenerative Therapies (BCRT), Charitéplatz 1, 10117 Berlin, Germany.
5. Department of Infectious Diseases, Department of Medicine IV, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.
6. German Center for Infection Research (DZIF), Partner Site Munich, Munich, Germany.
7. Department of Medicine IV, Division of Clinical Pharmacology, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.
8. Division of Infectious Diseases and Tropical Medicine, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.
9. COVID-19 Registry of the LMU Munich (CORKUM), University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.
10. Department of Medicine III, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.
11. Department of Medicine II, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.
12. Department of Psychiatry and Psychotherapy, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.

Corresponding authors. Email:

Julia.Roider@med.uni-muenchen.de, Julia.Sbierski-Kind@med.uni-tuebingen.de

Department of Medicine IV, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.
Abstract

Innate lymphoid cells (ILCs) are key organizers of tissue immune responses and regulate tissue development, repair, and pathology. Persistent clinical sequelae beyond 12 weeks following acute COVID-19 disease, named post-COVID syndrome (PCS), are increasingly recognized in convalescent individuals. ILCs have been associated with the severity of COVID-19 symptoms but their role in the development of PCS remains poorly defined. Here we used multiparametric immune phenotyping, finding expanded circulating ILC precursors (ILCPs) and concurrent decreased group 2 innate lymphoid cells (ILC2s) in PCS patients compared to well-matched convalescent control groups at > 3 months after infection. Patients with PCS showed elevated expression of chemokines and cytokines associated with trafficking of immune cells (CCL19/MIP-3b, FLT3-ligand), endothelial inflammation and repair (CXCL1, EGF, RANTES, IL1RA, PDGF-AA). These results define immunological parameters associated with PCS and might help find biomarkers and disease-relevant therapeutic strategies.

Keywords

Innate lymphoid cells, COVID-19, Post-COVID-19-Syndrome, immune activation, tissue immunology

Abbreviations

EFG: epidermal growth factor
FLT-3 Ligand: Fms-related tyrosine kinase 3 ligand
IF-γ: interferon γ
ILC: Innate lymphoid cells
ILCP: Innate lymphoid cell precursors
ILC2s: Group 2 innate lymphoid cells
IL: interleukin
IL1RA: interleukin-1 receptor antagonist
PBMCs: Peripheral blood mononuclear cells
PAIS: Post-acute infection syndromes (PAIS)
PC: Post-Covid
PCS: Post-COVID-Syndrome
PDGF-AA: platelet-derived growth factor A
SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2
TNF: tumor necrosis factor
t-SNE: t-distributed stochastic neighbor embedding
VEGF: vascular endothelial growth factor
Introduction

Viral infections can result in chronic symptoms that persist in previously healthy convalescent individuals across a wide range of viral families, including Ebola virus, influenza, Epstein-Barr virus, and dengue fever\(^1\). The main symptoms are exertion intolerance, fatigue, neurocognitive and sensory impairment, sleep disturbances, flu-like symptoms, myalgia/arthralgia, and a plethora of nonspecific symptoms\(^2\). These post-acute infection syndromes (PAIS) are associated with autoimmunity and endothelial dysfunction, affecting both large and small vessels\(^3\); however, risk factors and the underlying pathophysiology remain largely unknown.

The COVID-19 pandemic, caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has led to an increasing prevalence of convalescent patients with prolonged and persistent sequelae following acute SARS-CoV-2 infection known as “long COVID” or “post-COVID syndrome”\(^5\). The estimated prevalence of PCS ranges from 5-50\(^\%\)\(^6\), thus presenting an enormous global health burden, and can affect both patients with mild or severe forms of acute COVID-19 disease\(^7\). Clinical symptoms include fatigue, malaise, depression, cognitive impairment, persistent cough, dyspnoea, palpitations, and headaches\(^8\). While the acute phase of COVID-19 has been extensively studied, providing health care professionals with efficient treatment options, the pathogenesis of PCS remains unclear, with current hypotheses including autoimmunity, latent virus reactivation, tissue, and endothelial damage\(^9\).

The extreme respiratory distress in patients with acute COVID-19 is mediated primarily by immunopathology and systemic inflammation. Pathological immune signatures suggestive of T cell exhaustion, delayed bystander CD8\(^+\) T cell activation, and higher plasma GM-CSF and CXCL10 levels are associated with severity of the disease\(^10,11,12\). Survivors of severe COVID-19 show persistent immune abnormalities, including elevated levels of pro-inflammatory cytokines\(^13\). In addition to systemic inflammation, SARS-CoV-2 infects endothelial cells, causing virus-mediated apoptosis and consecutive endotheliitis and, thus, may promote endothelial damage and increased recruitment of activated immune cells into the endothelium and surrounding tissue\(^14\).
Dysregulated respiratory CD8+ T cell responses may contribute to impaired tissue conditions and development of pulmonary sequelae\textsuperscript{15}. Recent work identified persistent immunological dysfunction in patients with post-acute sequelae of COVID-19, including highly activated innate immune cells and marked differences in specific circulating myeloid and lymphocyte populations\textsuperscript{16,17}.

Innate lymphoid cells (ILCs) are tissue-resident effector immune cells with crucial roles in normal tissue development and remodeling\textsuperscript{18,19}. These cells also participate in both protective and pathologic immune responses during lung tissue perturbation\textsuperscript{20,21}. Several studies detected a reduction in total circulating ILCs in severe COVID-19 patients, while relative group 2 innate lymphoid cells (ILC2) levels, particularly NKGD\textsuperscript{+} ILC2s, were increased\textsuperscript{22,23}. Although ILCs appear central to lung infection and repair, their role in PCS remains critically unexplored.

Here we used multicolor flow cytometry and multiplex cytokine assays on plasma from (1) healthy, uninfected controls (n=32, ‘HC’); (2) previously SARS-CoV-2-infected individuals in the convalescent phase without persistent symptoms (n=32, convalescent controls, ‘CC’); and (3) individuals with persistent symptoms following acute COVID-19 (n=27, post-COVID, ‘PC’) to identify specific immunological alterations, including ILCs, in PCS. Among the CC and PC groups, most participants were non-hospitalized during acute SARS-CoV-2 infection and CC and PC individuals had persistent symptoms for more than 12 weeks from the initial infection. We found expanded circulating ILC precursors (ILCPs) in PC individuals while ILC2s were decreased. Patients with persistent symptoms also displayed elevated pro-inflammatory cytokines (IL-8, IL-6), chemokines associated with trafficking of immune cells (CCL19/MIP-3b, FLT3-Ligand), and endothelial inflammation and repair (CXCL1, EGF, RANTES, PDGF-AA).

**Results and Discussion**

**Clinical characteristics of study participants**

Patients, enrolled in the Post-COVID-Care study at the LMU University Hospital Munich, presented with persistent symptoms for more than 12 weeks following acute SARS-CoV-2 infection (PC group; n=27) and were compared to convalescent patients without persistent symptoms (CC group; n=32) and healthy controls (HC
group; n=32), enrolled in the KoCo19-index study (Fig. 1A). Clinical demographics of both study cohorts are reported in Table 1. The PCS, convalescent, and healthy control groups were well-matched in sex (67% female PC; 56% female CC; 53% female HC; Chi-square: 1.185, d.f. = 2), age (mean 37.15 years old PC; mean 36.09 years old CC; mean 35.91 years old HC; Kruskal-Wallis test p=0.9276), and BMI (mean BMI PC group 24.0kg/m²; mean BMI CC group 23.4kg/m²; mean BMI HC group 25.2kg/m²; Kruskal-Wallis test p=0.3315) (Fig. 1B and Table 1). Only 2 patients with COVID-19 sequelae were hospitalized during acute infection, whereas none of the convalescent study participants were hospitalized (Fig. 1C), reflecting that some patients experience long-term health-consequences after acute COVID-19, regardless of disease severity. For PC and CC groups, elapsed days since initial SARS-CoV-2 infection were different in median times from acute disease (113 days for PC group vs. 273 days for CC group; Mann-Whitney p= <0.0001) (Fig. 1D); however, initial enrolment and collection of blood for immunophenotyping took place more than 3 months after onset of COVID-19 and none of the convalescent participants reported persistent symptoms after acute disease. Acute SARS-CoV-2 infections within the PC group occurred in the period when the Omicron BA.2 variants were dominant (between January and March 2022), whereas participants of the convalescent group were confirmed to be infected with SARS-CoV-2 between March and April 2020, when parental strains drove the majority of new cases. While several risk factors, including comorbidities and virus variants, have been identified for the development of PCS²⁴, clinical symptoms are similar for different SARS-CoV-2 strains, with the exception of musculoskeletal pain, where chronic burden may be lower for Omicron compared to Delta variants²⁵. Consistent with numerous previous reports of PCS, the most common reported symptoms included constitutional symptoms, such as fatigue (93%) and insomnia (41%), and neurological symptoms, such as impaired alertness (74%), memory impairment (59%), and impaired speech (56%). Cardiac symptoms, including palpitations (59%), chest pain (52%), and reduced muscular strength (26%) were also a common complaint (Fig. 1E).

Pro-inflammatory cytokines and growth factors are elevated in PCS

In COVID-19 patients with severe disease, cytokine storm and uncontrolled inflammatory responses, including endothelial inflammation and associated tissue damage, are recognized as one of the driving immunopathological features that can
lead to death\textsuperscript{10}. To uncover the immunological dysregulation in PCS, we quantified 46 molecular analytes in the plasma of patients from the CC and PC groups >3 months after acute SARS-CoV-2 infection using a multiplex cytokine assay and compared them to healthy controls. Four key pro-inflammatory cytokines (interleukin-8 (IL-8), IL-6, interleukin-1 receptor antagonist (IL-1Ra) and IL-1α) were elevated in the PC group compared to the CC and HC groups (Fig. 2A, Suppl. Fig. 1), while no difference was observed in transforming growth factor alpha (TGF-α), IL-7, IL-5, IL-4, IL-13, IL-10, tumor necrosis factor (TNFα), interferon γ (IFN-γ) and IL-1β (Suppl. Fig. 1). IL-8 has been previously associated with a prothrombotic neutrophil phenotype in severe COVID-19 and blocking IL-8 signaling reduced SARS-CoV-2 spike protein-induced, human ACE2-dependent pulmonary microthrombosis in mice\textsuperscript{26}. Surprisingly, levels of IL-8 and IL-6 were lower in CC compared to HCs, whereas other pro-inflammatory cytokines were not different between these groups (Fig. 2A, Suppl. Fig. 1). IL-1Ra was 2.16-fold higher in the PC group compared to the HC group and 2.22-fold higher compared to the CC group; other pro-inflammatory cytokines were only slightly increased (Fig. 2A, Suppl. Fig.1). Several chemokines (RANTES, MIP3b, CXCL1) and growth factors (Fms-related tyrosine kinase 3 ligand (FLT-3 Ligand), epidermal growth factor (EGF), vascular endothelial growth factor (VEGF), platelet-derived growth factor A (PDGF-AA)), that could be associated with trafficking of immune cells (MIP3b, FLT3-Ligand) and endothelial inflammation (CXCL1, EGF, RANTES, PDGF-AA), CD40L and Granzyme B were also elevated in PC participants compared to both CC and HC groups (Fig. 2A, Suppl. Fig.1). Interestingly, Eotaxin (CCL11), monocyte chemoattractant protein 1 (MCP1), and IL-12p70 were decreased in PC patients compared to both convalescent and healthy controls (Suppl. Fig. 1); some of these chemokines were associated with severe cases of acute COVID-19\textsuperscript{27}. Importantly, programmed death-ligand 1 (PD-L1) was increased in the persistent symptom group compared to both convalescent and healthy control groups, consistent with previous reports, highlighting the prognostic role of sPD-L1 in COVID-19 patients\textsuperscript{28} (Suppl. Fig.1). Although most plasma samples from the CC group were taken at month 8 after acute COVID-19 infection while samples from the PC group were taken at month 4, challenging direct comparison of persistent symptom and convalescent groups, several studies have shown that pro-inflammatory cytokines remained significantly elevated in PC patients at month 8 after acute infection\textsuperscript{17}. Together, these data
suggest persistent immune abnormalities in patients suffering from post-acute sequelae of COVID-19.

Circulating ILCs are elevated in PC patients with concurrent decrease in ILC2s

To investigate circulating ILC levels via flow cytometry in PCS, convalescent and healthy controls, we used a well-established gating strategy\(^\text{29}\) (Suppl. Fig. 2). Lin\(^-\) CD127\(^+\) ILC subsets were defined as CD117\(^-\)CRTH2\(^-\) ILC1s, CD117\(^+\) ILC progenitors (ILCP)\(^30\), and CRTH2\(^+\) ILC2s. We used CD56 as a marker of activated or ILC3/NK cell-committed ILCP and CD45RA for naïve ILCP\(^29\). Recent work discovered CD45RA\(^+\) naïve-like ILCs, lacking proliferative activity, indicative of cellular quiescence\(^31\). To visualize multiple dimensions in simple two dimensional plots and compare flow cytometry data between groups, we used stochastic neighbor embedding analysis (Fig. 2 B, C). We found increased expression of the ILCP marker CD117 in PC compared to HC groups, while CRTH2 (marker for ILC2s) was decreased in PC compared to both CC and HC groups (Fig. 2B, C). However, the expression of proteins associated with ILC activation, CD56 (also defining NK cells with intermediate or high expression levels) and HLA-DR, was not different between groups (Fig. 2B, C). Next, we evaluated total numbers and frequencies of circulating ILCs and NK cells in patients with persistent symptoms after COVID-19 infection as compared to convalescent patients and healthy controls. We did not observe significant changes in total ILCs and subsequent ILC subsets (ILC2s, ILC1s, ILCPs) in PC compared to CC and HC groups (Suppl. Fig. 3A). However, PC patients had expanded levels of ILCPs with concurrent decreased ILC2 frequencies, while ILC1 levels remained unchanged (Fig. 2 D, E). The role of ILC2s in viral-induced lung pathogenesis remains controversial. Although increased levels of IL-18, IL-13, and IL-6 have been reported along with accumulation of ILC2s during acute COVID-19, increased circulating ILC2s in moderate but not severe COVID-19 patients were found in other studies\(^32\), consistent with their attrition by IFN-\(\gamma\) in type 1 (viral-induced) inflammation\(^20\). Thus, ILC2s might have important roles in tissue repair during viral-induced epithelial cell damage, perhaps through crosstalk with other ILC subsets.

Recent work suggested that human ILCPs can interact with endothelial cells, fostering the adhesion of other innate and adaptive immune cells by stimulating pro-
inflammatory cytokine expression of adhesion molecules. This activation occurs through the tumor necrosis factor receptor- and RANK-dependent engagement of NF-κB pathway\(^3\). Nevertheless, PC patients did not show significant changes in CD45RA\(^+\) ILCPs, although CD56\(^+\) ILCPs were trending upwards, suggesting a circulating ILCP expansion without overt altered activation (Fig. 2E). Surprisingly, the expression of CD45RA was increased in both ILC1 and ILC2 subsets in the PC group compared to HC (Suppl. Fig. 3B), suggesting the increase of a quiescent local reservoir for the generation of differentiated ILCs\(^3\). Frequencies of HLA-DR\(^+\) ILC1s and the transcriptional expression of SLAMF1 within the ILC2 compartment were similar between PC, CC, and HC groups (Suppl. Fig. 3B). We could not find significant differences in NK cell frequencies between patients with PCS, convalescent, and healthy controls (Suppl. Fig. 3C). Together, these data indicate that ILCPs expand in patients with COVID-19 sequelae, without alteration of their activation state.

**Concluding remarks**

Persistent sequelae following acute COVID-19 are increasingly recognized in convalescent individuals. Our exploratory analyses identified immunological differences in patients with PCS as compared to well-matched convalescent and HC individuals at > 3 months post infection. We found significant changes in circulating ILC subsets, including increased ILCPs and concurrent decreased ILC2 levels. In addition, pro-inflammatory cytokines (IL-8, IL-6), chemokines associated with trafficking of immune cells (CCL19/MIP-3b, FLT3-Ligand) and endothelial inflammation and -repair (CXCL1, EGF, RANTES, PDGF-AA) were elevated in PC participants. Although our work does not dissect how ILCPs or other activated innate and adaptive immune cells, contribute mechanistically to endothelial dysfunction in PCS, ILCP expansion along with elevated markers for endothelial inflammation in PC supports their interaction with endothelial cells; thereby facilitating enhanced inflammatory responses and endotheliitis in several organs. These findings may not only be interesting for long-term sequelae of COVID-19, but also for other viral infections that can result in PAIS in convalescent individuals. Further exploration of immunological alterations in PCS may delineate mechanisms of ILC-endothelial cell crosstalk and lead to disease-relevant targeted therapies.
Data availability statement: Further information and requests for resources and reagents should be delivered to and will be fulfilled by the Lead Contact, Julia Roider (Julia.Roider@med.uni-muenchen.de).

Conflict of Interest: The authors declare no commercial or financial conflicts of interest.

Ethics approval statement for human studies: KoCo19 Shield: The study protocol was reviewed and approved by the Institutional Review Board of the Medical Faculty at Ludwig-Maximilians-University Munich, Germany under the project number 20-692 (vote of approval dated Sept. 21st, 2020) and 20-371 (vote of approval dated May 15th, 2020). Oral and written informed consent was obtained from all study subjects. PCC: The study protocol was reviewed and approved by the Institutional Review Board of the Medical Faculty at Ludwig-Maximilians-University Munich, Germany under the project number 21-1165 (vote of approval dated Feb 15, 2021, amendment approved Aug. 11, 2021). Oral and written informed consent was obtained from all study subjects.

Patient consent statement: The patients/participants provided their written informed consent to participate in this study.

Author contributions: Conception and design: JR and JSK. Cohort initiation, study follow-up, data management and sample processing KoCo19 Shield: MH, MP, CP, IB, LG, NW. Cohort initiation, study follow-up, data management and sample processing PCC: HS, KA, US, JB, GI, EG, MR, CB, AP, EV. Acquisition of data: JSK, SF, VO, HS, MA. Analysis and interpretation of data: JSK and SS. Writing of the manuscript: JSK and JR. Critical reagents and manuscript editing: SF, VO, SS, and MA. Funding acquisition: MH, HS, KA, JSK, JR.

Acknowledgements: We thank Renate Stirner and Gabriele Reiling for excellent technical assistance. The Post-COVIDLMU research project is financially supported by the Bavarian State Ministry for Health and Care and the Bavarian State Office for Health and Food Safety (LGL). There is a close link to the nationwide research project "Network University Medicine" (NUM), funded by the Federal Ministry of Education and Research (BMBF) (funding code: 01KX2021) and the NUM-associated research projects. JR is supported by the German Center for Infection Research (DZIF) and Else Kröner-Fresenius-Stiftung (EKFS). JSK received funding
from the German Research Foundation (DFG, Deutsche Forschungsgemeinschaft), the German Diabetes Society (DDG, Deutsche Diabetes Gesellschaft), and FoeFoLe, LMU Munich. JSK is also supported by the German Society of Internal Medicine (DGIM, Deutsche Gesellschaft für Innere Medizin, Clinician Scientist Program).
**Figures and Figure Legends**

**Table 1: Clinical and demographic characteristics of study cohorts.** Data are given as numbers (percentages). BMI, body mass index. Sex, age and BMI were comparable between groups with an overall mean age of 36 years, 58% females and BMI of 24.2kg/m².

**Figure 1: Clinical characteristics of study cohorts.**
(A) Overview of study cohorts and methods. The figure is partly created with BioRender.com.
(B) Demographic characteristics for healthy controls with no prior SARS-CoV-2 infection (HC), convalescent SARS-CoV-2 participants without persisting symptoms (CC) and convalescent SARS-CoV-2 participants with persisting symptoms (PC) displayed as ring charts. Statistical significance is shown by capped lines as Chi-square tests for ‘Sex’ and post-hoc comparisons for ‘Age’. Characteristics are further detailed in Table 1.
(C) Percentage of hospitalization during acute Covid infection for CC and PC participants displayed as ring charts.
(D) Box plots showing days from first positive PCR test for CC and PC groups. Central lines indicate group means; top and bottom lines indicate minimum and maximum. Significance was assessed by Mann-Whitney-test.
(E) Prevalence of top 22 self-reported symptoms in PC participants ranked from least prevalent (left) to most prevalent (right). Symptoms are colored according to physiological systems. Gastrointestinal (GI), endocrine (Endo), pulmonary (Pulm), constitutional (Const), neurological (Neuro), cardiac, and musculoskeletal (MSK).

***p ≤ 0.0001. See also Table 1.

**Figure 2: Post-COVID participants show altered cytokine expression and levels of innate lymphoid cells.**
(A) Multiplex assay quantification showing plasma levels of IL-8, IL-6, IL-1RA, RANTES, FLT-3 Ligand and EGF in healthy controls with no prior SARS-CoV-2 infection (HC), convalescent SARS-CoV-2 participants without persisting symptoms (CC), and convalescent SARS-CoV-2 participants with persisting symptoms (PC) at 3-10 months after acute COVID infection.
(B) High-dimensionality reduction analysis of innate lymphoid cells (ILCs, gated as lymphocytes, singlets, and CD45⁺CD3⁻Lin⁺CD127⁺ cells as shown in Supplementary Figure 3) from peripheral blood mononuclear cells (PBMCs) of HC, CC, and PC groups. High-resolution group differences were visualized by calculating Cohen’s D.
for a given comparison across the t-SNE map. Residual plot showing differences between maps. Phenotypes within red circles were confirmed to be statistically more common in PC samples, and phenotypes within blue circles were less common in PC samples. Analysis is based on flow cytometry data from 32 HC, 32, CC, and 27 PC samples.

(C) Relative expression intensities (combined HC, CC, and PC samples) of parameters used in the t-SNE analysis.

(D and E) Representative flow cytometry plots (D) and quantification (D and E), showing percent innate lymphoid cell populations in HC, CC, and PC groups at 3-10 months after acute COVID infection. Bar graphs indicate mean (±SE), n=27-32 individuals per group, unpaired t-test (A, D, E), *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001. See also Supplementary Figure 1.
Materials and Methods

Study design

KoCo19-Shield sub study of the prospective Covid19 cohort Munich -Index study (KoCo19-Index)

To establish the KoCo19-index cohort, we recruited study subjects in whose household at least one person had a PCR confirmed SARS-CoV-2 infection. Recruitment was performed as previously described\textsuperscript{34}. In brief, individuals with PCR confirmed SARS-CoV2 infection were contacted by the responsible official authorities (City of Munich Health department) in May and June 2020. Individuals who expressed interest in participating were enrolled in the KoCo19 index study. For the KoCo19 – Shield sub study, at least one member of the participant’s household (> 14 years old) also had to be willing to participate. The KoCo19-Shield sub study comprised 177 PCR-positive individuals and 145 household members, enrolled between September 29, 2020, and January 27, 2021. Personal data of the study subjects was collected as previously described\textsuperscript{35}. In short, the mobile data collection tool OpenDataKit (ODK) was used to capture data during study visits by field workers on Android smartphones. Study subjects completed household questionnaires as well as personal questionnaires using a web-based application. Non-responders were reminded first by email, and in case of continued non-response with a telephone reminder. Telephone interviews were offered to those who felt unable to complete the questionnaires online. Clinical demographics of study participants are reported in Table 1.

The study was approved by the Ethics Committee of the Medical Faculty at LMU Munich (20–275 V) and the protocol is available online (www.koco19.de)\textsuperscript{34}. Informed consent was obtained from all enrolled participants. The study is registered to the German Clinical Trials Register (DRKS-ID: DRKS00022155).

Post Covid Study

Post-COVID-Care (PCC) study is an ongoing prospective single-center study comprised of patients with persistent symptoms following acute COVID-19. Participants with COVID-19 sequelae were recruited from the Post-COVID outpatient clinic at the University Hospital LMU Munich. Samples were collected from participants enrolled between April and July 2022. Inclusion criteria were age ≥ 18...
years; persistent symptoms > 12 weeks within 6 months following initial COVID-19 infection. Pre-specified exclusion criteria were other explanations for the symptom onset or complete resolution of symptoms. All participants were scheduled for follow-up for at least 6 months and up to 24 months if symptoms persisted. At baseline and during the routine follow-up visits blood samples were obtained and each patient completed progressive web app (PWA)-based questionnaires (LCARS-C, LMU Munich). Patients who did not undergo any follow-up on site were asked to fill out the follow-up surveys using the PWA-based questionnaire at home using a PC, smartphone or tablet. Informed consent was obtained from all participants before inclusion into the study. Clinical characteristics of study participants are reported in Table 1. The study was approved by the Ethics Committee of the Medical Faculty at LMU Munich (No. 21-1165) and registered to the German Clinical Trials Register (DRKS-ID: DRKS00030974).

Participant Surveys

KoCo19 and PCC study participants completed a comprehensive suite of surveys, combining validated patient-reported outcomes (PROs) with custom, purpose-developed tools by the study team. Baseline demographic data collected from surveys included gender, age, body mass index (BMI), race, and medical comorbidities. Additionally, participants in the Long COVID and convalescent group were asked to provide COVID-19 clinical data including date of symptom onset and acute disease severity (non-hospitalized vs. hospitalized), SARS-CoV-2 polymerase chain reaction (PCR) diagnostic testing results, and SARS-CoV-2 antibody testing results. All participants were asked to report SARS-CoV-2 vaccination status including date of vaccinations and vaccine brand.

Blood sample processing

Whole blood was collected in four potassium-EDTA-coated blood collection tubes (Sarstedt) from participants at University Hospital, LMU, Munich, Germany. Following blood draw, all participant samples were assigned unique study identifiers and de-identified by research staff. Blood samples were processed the same day as collection. Plasma samples were collected after centrifugation of whole blood at 450×g for 10 minutes at room temperature (RT). Plasma was then transferred to 1,8-ml polyethylene Cryotube™ vials (ThermoFisher), aliquoted, and stored at -80°C. For
isolation of peripheral blood mononuclear cells (PBMCs), two tubes each of the remaining whole blood sample were pooled and filled up to a total volume of 32.5 ml with Hank’s Balanced Salts Solution (Capricorn or Sigma). 13.5ml Histopaque®-1077 (Sigma) were added at the bottom of each tube and samples were centrifuged at 450xg for 30 minutes at RT without break. PBMC layer on top of the Histopaque® layer was collected and washed twice in Hank’s balanced salts solution. Isolated cells were counted using a CASY cell counter and analyzer (Schärfe System GmbH) before storage in liquid nitrogen at -180°C for cryopreservation.

Flow cytometry
Cryopreserved PBMCs were thawed in a 37°C water bath, pipetted into Iscove’s Modified Dulbecco’s Medium (IMDM) supplemented with 10% FCS medium, and washed by centrifugation. Three to six million cells per sample were incubated with antibodies to surface antigens (Table S1) for 30 minutes at 4°C, washed with FACS buffer (1XDPBS, 3% FCS, 0.05% NaN₃), fixed with 2% paraformaldehyde for 10 minutes, washed again with FACS buffer, and resuspended in FACS buffer. Flow cytometry was performed on BD LSRFortessa X-20. Fluorochrome compensation was performed with single-stained UltraComp eBeads (Invitrogen, Cat# 01-2222-42). Samples were FSC-A/SSC-A gated to exclude debris, followed by FSC-H/FSC-A gating to select single cells and Zombie NIR fixable or DAPI to exclude dead cells. Innate lymphoid cells were identified as lineage negative (CD1a<sup>-</sup>, CD14<sup>-</sup>, CD19<sup>-</sup>, CD34<sup>-</sup>, CD94<sup>-</sup>, CD123<sup>-</sup>, FcER1α<sup>-</sup>, TCRαβ<sup>-</sup>, TCRγδ<sup>-</sup>, BDCA2<sup>-</sup>), CD45<sup>+</sup>, CD161<sup>+</sup>, CD127<sup>+</sup>, as indicated. The full gating strategy is shown in Fig. S1 and was adapted from previous work<sup>29</sup>. Data were analyzed using FlowJo version 10.7 software (TreeStar, USA) and compiled using Prism (GraphPad Software). T-distributed stochastic neighbor embedding (t-SNE) visualization of flow cytometry data was performed using Cytobank.

Quantification of plasma cytokine levels
The plasma levels of 46 molecular species were quantified using a Luminex platform (Human Cytokine Discovery, R&D System, Minneapolis, MN) for the simultaneous detection of the following molecules: G-CSF, PDGF-AA, EGF, PDGF-AB/BB, VEGF, GM-CSF, FGF, GRZB, IL-1A, IL-1RA, IL-2, IL-27, IL-4, IL-6, IL-10, IL-13, TNF, IL-
17C, IL-11, IL-18, IL-23, IL-6RA, IL-19, IFN-B, IL-3, IL-5, IL-7, IL-12p70, IL-15, IL-33, TGF-B, IFN-G, IL-1B, IL-17, IL-17E, CCL3, CCL11, CCL20, CXCCL1, CXCL2, CCL5, CCL2, CCL4, CCL19, CXCL1, CXCL10, PD-L1, FLT-3, TACI, FAS, LEPTIN R, APRIL, OPN, BAFF, LEPTIN, BMP4, CD40 LIGAND, FAS LIGAND, BMP7, BMP2, and TRAIL, according to the manufacturer’s instruction

**Statistical analysis**

All data are expressed as means ± standard error of the mean (SEM) unless otherwise noted. Comparisons between two groups were analyzed by using unpaired two-tailed Student’s t-tests, and multiple comparisons were analyzed by one-way analysis of variance (ANOVA) with Tukey’s multiple comparisons test (Prism, GraphPad Software, La Jolla, CA), with * = p<0.05, ** = p<0.01, *** =p<0.001, **** =p<0.0001. Each symbol reflects individuals for flow analysis or plasma cytokine levels.

**Unsupervised data analysis.** Cytobank\textsuperscript{36} was used for initial manual gating of Lineage-negative cells and ILC subsets ILC1, ILC2, and ILCP, using the same gating strategy as described above. FCS files were transformed with. Lineage-negative cells were subjected to dimensionality reduction using Cytobank opt-SNE with default hyperparameters and following embedding markers with normalized scales Cytobank arcsinh transformation: CD117, CD127, CD161, CD45RA, CD56, CRTH2, HLA-DR, and SLAMF1. All pre-gated events were used without prior downsampling from 91 samples. In order to perform downstream statistical analyses in R (http://www.r-project.org/) and visualize t-SNE maps across the 91 samples, events within ILC subsets were exported from Cytobank as tab-separated values containing compensated and transformed marker expression levels as well as t-SNE coordinates and metacluster assignment. T-SNE plots were generated after subsampling each sample to contain a maximum of 2500 events. High-resolution group differences were visualized by calculating Cohen’s D for a given comparison across the t-SNE map. To this end, we generated adaptive 2D histograms using the probability binning algorithm available through the R flowFP package\textsuperscript{37}. Dependent on the total number of cells available, a single binning model was created on collapsed data from all samples, by recursively splitting the events at the median values along the two t-SNE dimensions. We chose a grid of 256 bins to have, on
average, at least eight cells per bin in each sample for statistical accuracy. Since there was a significant difference between cellular frequency distributions between the six measurement days, the batch effect was first regressed out by fitting a linear model to each bin after applying the arcsine-square-root transformation for proportions. The group-difference effect sizes were then calculated for each bin using the cohen.d function of the `effsize` package. In order to get a smoothed representation of the effect size map, adaptive binning was performed on a series of rotated coordinates and per cell-averaged effect size values were used to color-code each cell throughout the t-SNE map. All analyses were performed using R version 4.1.1, available free online at https://www.r-project.org.

**Post Covid Care group members**


**KoCo19 study group members**

References


2. A Post-Graduate Lecture ON THE NERVOUS SEQUELÆ OF INFLUENZA. *Lancet.* 1893;142(3645):73-76. doi:https://doi.org/10.1016/S0140-6736(00)65088-2


11. Bergamaschi L, Mescia F, Turner L, et al. Longitudinal analysis reveals that...


Figure 1

A) KoCo-shield cohort and Post-COVID-Care cohort.

B) Sex and age distribution for HC, CC, and PC groups.

C) Acute Covid severity: CC and PC.

D) Days from acute COVID-19.

E) Prevalence of symptoms: GI, Neuro, Pulm, Cardiac, Endo, MSK.
Figure 2

A: Dot plots showing the levels of various cytokines and chemokines in HC, CC, and PC groups. The y-axis represents the concentration (pg/ml) of IL-8, IL-6, IL-1RA, RANTES, FLT-3 Ligand, and EGF for different groups.

B: t-SNE plots comparing HC vs. CC, HC vs. PC, and CC vs. PC. The plots show the distribution of cells in the two-dimensional space.

C: Heatmaps depicting the expression levels of CD45RA, SLAMF1, and HLADR in different groups. The colors represent the expression levels with a gradient scale.

D: Dot plots showing the percentage of ILCp, ILC1, and ILC2 in HC, CC, and PC groups, with the percentage of CD45RA+ and CD56+ cells also indicated.

E: Bar graphs showing the percentage of ILC, ILC1, ILC2, ILCp, CD56+, and CD45RA+ cells in different groups.
Table 1. Clinical characteristics of patient cohorts

<table>
<thead>
<tr>
<th></th>
<th>Healthy Controls (HC)</th>
<th>Convalescent Controls (CC)</th>
<th>Post Covid (PC)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>n</strong></td>
<td>32</td>
<td>32</td>
<td>27</td>
</tr>
<tr>
<td><strong>Sex</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>15 (46.9%)</td>
<td>14 (43.8%)</td>
<td>9 (33.3%)</td>
</tr>
<tr>
<td>Female</td>
<td>17 (53.1%)</td>
<td>18 (56.2%)</td>
<td>18 (66.7%)</td>
</tr>
<tr>
<td><strong>Age (years)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20-29</td>
<td>6 (18.8%)</td>
<td>6 (18.8%)</td>
<td>4 (14.8%)</td>
</tr>
<tr>
<td>30-39</td>
<td>10 (31.2%)</td>
<td>12 (37.5%)</td>
<td>10 (37.0%)</td>
</tr>
<tr>
<td>40-49</td>
<td>15 (46.9%)</td>
<td>12 (37.5%)</td>
<td>8 (29.6%)</td>
</tr>
<tr>
<td>&gt;49</td>
<td>1 (3.1%)</td>
<td>2 (6.2%)</td>
<td>5 (18.5%)</td>
</tr>
<tr>
<td><strong>BMI (kg/m²)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;18.5</td>
<td>3 (9.4%)</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>18.5-25</td>
<td>14 (43.8%)</td>
<td>22 (68.8%)</td>
<td>15 (55.6%)</td>
</tr>
<tr>
<td>25-30</td>
<td>10 (31.2%)</td>
<td>9 (28.1%)</td>
<td>4 (14.8%)</td>
</tr>
<tr>
<td>&gt;30</td>
<td>5 (13.6%)</td>
<td>1 (3.1%)</td>
<td>3 (11.1%)</td>
</tr>
<tr>
<td><strong>Mean</strong></td>
<td>25.2</td>
<td>23.4</td>
<td>24</td>
</tr>
<tr>
<td><strong>Time from PCR to visit</strong></td>
<td>273 (Min:125; Max: 318)</td>
<td>113 (Min: 89; Max: 292)</td>
<td></td>
</tr>
</tbody>
</table>

Data are given as numbers (percentages). BMI, body mass index.

Sex, age and BMI were comparable between groups with an overall mean age of 36 years, 58% females and BMI of 24.2kg/m2.